Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 28, Issue 1, 2012, Pages 119-125

  Lewczuk, Piotr ^a   Popp, Julius ^b,c   Lelental, Natalia ^a   Kölsch, Heike ^c   Maier, Wolfgang ^c,d   Kornhuber, Johannes ^a   Jessen, Frank ^c,d  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF BONN   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; amyloid protein precursor; biomarkers; cerebrospinal fluid

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONTROLLED STUDY; FEMALE; GENOTYPE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 84855796427     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110857     Document Type: Article

References (17)

1. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J (2006) Therapeutic approaches to Alzheimers disease. Brain 129, 2840-2855.
2. Hull M, Berger M, HenekaM(2006) Disease-modifying therapies in Alzheimers disease: How far have we come? Drugs 66, 2075-2093. (Pubitemid 46372359)
3. The Working Group on: "Molecular and Biochemical Markers of Alzheimers Disease"(1998) Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimers Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimers Association and the National Institute on AgingWorking Group. Neurobiol Aging 19, 109-116.
4. Lewczuk P, Wiltfang J (2008) Neurochemical dementia diagnostics: State of the art and research perspectives. Proteomics 8, 1292-1301. (Pubitemid 351462934)
5. Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J (2009) Neurochemical dementia diagnostics: A simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 116, 1163-1167.
6. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L, Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hull M, Schroder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kolsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimers disease: A multicenter study. Mol Psychiatry 15, 138-145.
7. Popp J, Lewczuk P, Frommann I, Kolsch H, Kornhuber J, Maier W, Jessen F (2010) Cerebrospinal fluid markers for Alzheimers disease over the lifespan: Effects of age and the APOEepsilon4 genotype. J Alzheimers Dis 22, 459-468.
8. Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kolsch H, Jessen F, Schroder J, Schonknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J (2008) Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiol Aging 29, 812-818. (Pubitemid 351601894)
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, StadlanEM(1984) Clinical diagnosis of Alzheimers disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimers disease. Neurology 34, 939-944. (Pubitemid 14076461)
10. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246. (Pubitemid 39222993)
11. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
12. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimers disease: Recommendations from the National Institute on Aging-Alzheimers associationworkgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 7, 263-269.
13. Gabelle A, Roche S, Geny C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Chaulet C, Vighetto A, Croisile B, Krolak-Salmon P, Touchon J, Perret-Liaudet A, Lehmann S (2010) Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Brain Res 1357, 175-183.
14. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, Karhunen PJ (2009) Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 65, 650-657.
15. Mahley RW, Weisgraber KH, HuangY(2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimers disease. Proc Natl Acad Sci U S A 103, 5644-5651.
16. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Forstl H, Kurz A, Alexopoulos P (2011) CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology 77, 35-38.
17. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J Cerebrospinal fluid biomarkers for Alzheimers disease: Diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis 24, 537-546.